Latest From Biotech Now

Partners for Healthy Dialogues: Letter to CMS

Partners for Health Dialogues

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in a letter to the Center for Medicare and Medicaid Services highlighting both their shared commitment to sunshine and the importance of context in the upcoming data release.  As BIO CEO Jim Greenwood said in a Q&A with P4HD: “We believe that part of CMS’s public service function in this area should be to help improve the public’s understanding of the need for Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Report Shows Biotech Crop Varieties Continue to be Preferred By U.S. Farmers

USDA ERS Logo

Tom Saidak reported for BioBased Digest on the latest U.S. adoption data for genetically engineered varieties of corn, cotton and soybeans. In Washington, BIO commented on the USDA’s Economic Research Service Report, Genetically engineered varieties of corn, upland cotton, and soybeans, by State and for the Unites States, 2000-14. Key findings for 2014 included 94 percent of all soybeans grown in the U.S., 93 percent of all corn, and 96 percent of all cotton are Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

medicine-thumb

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how ObamaCare is already bending the future of U.S. medical progress, consult the furor over specialty drug prices, as an alliance of convenience among third-party payers assails pharmaceutical innovation as too costly. Maybe patients should give up on cures and, as President Obama once put it, just take the painkiller…” Read the full opinion

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The ‘What’s the Point’ Category for GMO Labeling Bills

label

Lawmakers have so much work to do, and few days left in which to do it. Formal sessions will end July 31. These bills and a slew of others should be organized under a new heading: ‘Don’t Bother.’ –The Boston Herald “A Back Burner Beckons,” July 21, 2014 Vermont has recently passed a state law that requires food manufacturers to label certain foods made with genetically modified organisms (GMOs). Vermont’s next door neighbor, Massachusetts, has similar Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,